All In Biotech

Drug Trial Radar · NCT03682068

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer.

Last checked: Nov 20, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,246 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,246

Actual

Start

Sep 27, 2018

Primary completion

Jun 1, 2026

Study completion Jun 1, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 24, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra).

Conditions

  • Unresectable Locally Advanced Urothelial Cancer
  • Metastatic Urothelial Cancer

Interventions

  • DurvalumabDrug

    Durvalumab IV (intravenous infusion)

  • TremelimumabDrug

    Tremelimumab IV (intravenous infusion)

  • Cisplatin + GemcitabineDrug

    Cisplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.

  • Carboplatin + GemcitabineDrug

    Carboplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: approximately 5 years

Locations

222 sites in 22 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Bakersfield, California

  • Research Site

    Fullerton, California

  • Research Site

    Los Angeles, California

  • Research Site

    Salinas, California

  • Research Site

    Santa Barbara, California

  • Research Site

    Truckee, California

  • Research Site

    New Haven, Connecticut

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Orlando, Florida

  • Research Site

    Chicago, Illinois

  • Research Site

    Fort Wayne, Indiana

  • Research Site

    Kansas City, Kansas

  • Research Site

    Louisville, Kentucky

  • Research Site

    New Orleans, Louisiana

  • Research Site

    Grand Rapids, Michigan

  • Research Site

    Bozeman, Montana

  • Research Site

    New Hyde Park, New York

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Rochester, New York

  • Research Site

    Germantown, Tennessee

  • Research Site

    Fort Worth, Texas

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    Box Hill, Australia

  • Research Site

    Elizabeth Vale, Australia

  • Research Site

    Kogarah, Australia

  • Research Site

    Macquarie University, Australia

  • Research Site

    Murdoch, Australia

  • Research Site

    Orange, Australia

  • Research Site

    South Brisbane, Australia

  • Research Site

    St Albans, Australia

  • Research Site

    Curitiba, Brazil

  • Research Site

    Fortaleza, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

Showing 40 of 222 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.